EV-302 results ‘a leap forward’ for advanced urothelial carcinoma
![Illustration of bladder cancer](https://www.medwirenews.com/wp-content/uploads/2022/07/AdobeStock_49608511_bladder-cancer.jpg)
Phase 3 trial findings demonstrate a significant improvement in overall survival for patients with treatment-naïve, advanced urothelial carcinoma who receive a combination of enfortumab vedotin and pembrolizumab compared with chemotherapy.